Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: A case report and literature review

Medical Mycology

Volumn 49, Issue 8, 2011, Pages 872-878

  Liu, Jyh You ^a   Chen, Wei Ting ^b   Ko, Bor Sheng ^a   Yao, Ming ^a   Hsueh, Po Ren ^a   Hsiao, Cheng Hsiang ^a   Kuo, Yu Min ^a   Chen, Yee Chun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

Author keywords

Alemtuzumab; Combination antifungal therapy; Fusariosis; Fusarium infection; Voriconazole

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B DEOXYCHOLATE; CILASTATIN PLUS IMIPENEM; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GEMCITABINE; MITOXANTRONE; VANCOMYCIN; VORICONAZOLE;

ADULT; ANTIBIOTIC THERAPY; ANTIFUNGAL SUSCEPTIBILITY; CASE REPORT; CUTANEOUS T CELL LYMPHOMA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FUSARIOSIS; FUSARIUM SOLANI; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LOADING DRUG DOSE; LYMPHOID CELL; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUTH LESION; NEUTROPENIA; NONHUMAN; ODYNOPHAGIA; REVIEW; SKIN BIOPSY; SKIN DEFECT; SKIN NECROSIS; TUMOR;

ADULT; AMPHOTERICIN B; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DEOXYCHOLIC ACID; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEVER; FUSARIOSIS; FUSARIUM; GRANULOCYTES; HUMANS; IMMUNOCOMPROMISED HOST; LEUKOCYTE TRANSFUSION; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PYRIMIDINES; SKIN NEOPLASMS; TRIAZOLES;

FUSARIUM;

EID: 80054699921     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.567304     Document Type: Review

References (39)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917. (Pubitemid 34229758)
2. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704. (Pubitemid 47623773)
3. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as f rst-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18: 484-490. (Pubitemid 38425862)
4. Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lym-phocytic leukemia. Oncologist 2008; 13: 167-174. (Pubitemid 351342581)
5. Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43: 16-24. (Pubitemid 43939071)
6. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204-212. (Pubitemid 46079982)
7. Thursky KA, Worth LJ, Seymour JF, Miles PH, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alem-tuzumab. Br J Haematol 2006; 132: 3-12. (Pubitemid 43381565)
8. Hsiao CH, Li SY, Wang JL, Liu CM. Clinicopathologic and immuno-histochemical characteristics of fungal sinusitis. J Formos Med Assoc 2005; 104: 549-556.
9. Hsiue HC, Ruan SY, Kuo YL, Huang YT, Hsueh PR. Invasive infections caused by non-Aspergillus moulds identif ed by sequencing analysis at a tertiary care hospital in Taiwan, 2000-2008. Clin Micro-biol Infect 2010; 16: 1204-1206.
10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard-Second Edition. CLSI document M38-A2, 2008. Wayne, PA: Clinical and Laboratory Standards Institute.
11. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtu-zumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920-2924. (Pubitemid 38451660)
12. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003; 98: 773-778. (Pubitemid 36959274)
13. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003; 101: 4267-4272. (Pubitemid 36857787)
14. Gibbs SD, Westerman DA, McCormack C, Seymour JF, Miles PH. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 2005; 130: 87-91. (Pubitemid 40979137)
15. Lin TS, Flinn IW, Lucas MS, et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia 2005; 19: 1207-1210. (Pubitemid 40946005)
16. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98: 315-319. (Pubitemid 36828456)
17. Perfect JR. Treatment of non-Aspergillus moulds in immunocompro-mised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40: S401-408. (Pubitemid 40563297)
18. Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54: 4446-4450.
19. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131. (Pubitemid 36549632)
20. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-1403.
21. Rodriguez CA, Lujan-Zilbermann J, Woodard P, Andreansky M, Ad-derson EE. Successful treatment of disseminated fusariosis. Bone Marrow Transplant 2003; 31: 411-412.
22. Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2004; 23: 1059-1061. (Pubitemid 40824301)
23. Stanzani M, Vianelli N, Bandini G, et al. Successful treatment of disseminated fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. J Infect 2006; 53: e243-246. (Pubitemid 44688987)
24. Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 50: 227-231. (Pubitemid 46683972)
25. Tezcan G, Ozhak-Baysan B, Alastruey-Izquierdo A, et al. Disseminated fusariosis caused by Fusarium verticillioides in an acute lym-phoblastic leukemia patient after allogeneic hematopoietic stem cell transplantation. J Clin Microbiol 2009; 47: 278-281.
26. Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA. Disseminated Fusar-ium infection originating from paronychia in a neutropenic patient: a case report and review of the literature. Cutis 2010; 85: 191-194.
27. Durand-Joly I, Alfandari S, Benchikh Z, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol 2003; 41: 4898-4900. (Pubitemid 37259829)
28. Vagace JM, Sanz-Rodriguez C, Casado MS, et al. Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case report. BMC Infect Dis 2007; 7: 40.
29. Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and ampho-tericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother 2005; 39: 1365-1366. (Pubitemid 40943197)
30. Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinaf ne and am-photericin B. Ann Hematol 2004; 83: 394-397. (Pubitemid 38684455)
31. Neuburger S, Massenkeil G, Seibold M, et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal am-photericin B and terbinaf ne after allogeneic stem cell transplantation. Transpl Infect Dis 2008; 10: 290-293. (Pubitemid 352040435)
32. Cuellar-Rodriguez J, Bravo LT, Oethinger M, Fraser T, Mossad SB. Disseminated fusariosis in a recipient of a bone-marrow transplant. Lancet Infect Dis 2009; 9: 520.
33. Lewis R, Hogan H, Howell A, Safdar A. Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interfer-on-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leuk Lymphoma 2008; 49: 163-165. (Pubitemid 351146899)
34. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-247. (Pubitemid 34031636)
35. Heyn K, Tredup A, Salvenmoser S, Muller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Sce-dosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005; 49: 5157-5159. (Pubitemid 41778940)
36. Cordoba S, Rodero L, Vivot W, et al. In vitro interactions of antifun-gal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents 2008; 31: 171-174.
37. Ruiz-Cendoya M, Marine M, Guarro J. Combined therapy in treatment of murine infection by Fusarium solani. J Antimicrob Chemother 2008; 62: 543-546.
38. Ruiz-Cendoya M, Marine M, Rodriguez MM, Guarro J. Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. Antimicrob Agents Chemother 2009; 53: 1705-1708.
39. Ruiz-Cendoya M, Pastor FJ, Capilla J, Guarro J. Treatment of murine Fusarium verticillioides infection with liposomal amphotericin B plus terbinaf ne. Int J Antimicrob Agents 2011; 37: 58-61.